CoChat

Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea

Almeida, Camila Bononi, Souza, Lucas Eduardo Botelho, Leonardo, Flavia Costa, Costa, Fabio Trindade Maranhão, Werneck, Claudio C., Covas, Dimas Tadeu, Costa, Fernando Ferreira, Conran, Nicola · 2015 · Blood
Cited by 82

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Key Points: Hemolytic processes induce rapid systemic and vascular inflammation in C57BL/6 mice that is abolished by a single dose of hydroxyurea (HU). HU exerts some NO-dependent effects and should be investigated as an acute treatment of SCD and for other hemolytic disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2014-12-616250

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Research works printed but not linked: 41

  1. Olsson, 2012, Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for α(1)-microglobulin., Antioxid Redox Signal, 17, 813, 10.1089/ars.2011.4282 · DOI
  2. Wood, 2008, Sickle cell disease vasculopathy: a state of nitric oxide resistance., Free Radic Biol Med, 44, 1506, 10.1016/j.freeradbiomed.2008.01.008 · DOI · Paper page
  3. Yeo, 2009, Relationship of cell-free hemoglobin to impaired endothelial nitric oxide bioavailability and perfusion in severe falciparum malaria., J Infect Dis, 200, 1522, 10.1086/644641 · DOI · Paper page
  4. Vermeulen Windsant, 2012, Blood transfusions increase circulating plasma free hemoglobin levels and plasma nitric oxide consumption: a prospective observational pilot study., Crit Care, 16, R95, 10.1186/cc11359 · DOI
  5. Graça-Souza, 2002, Neutrophil activation by heme: implications for inflammatory processes., Blood, 99, 4160, 10.1182/blood.V99.11.4160 · DOI · Paper page
  6. Rother, 2005, The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease., JAMA, 293, 1653, 10.1001/jama.293.13.1653 · DOI · Paper page
  7. Vinchi, 2013, Hemopexin therapy improves cardiovascular function by preventing heme-induced endothelial toxicity in mouse models of hemolytic diseases., Circulation, 127, 1317, 10.1161/CIRCULATIONAHA.112.130179 · DOI · Paper page
  8. Conran, 2014, Intravascular hemolysis: a disease mechanism not to be ignored., Acta Haematol, 132, 97, 10.1159/000356836 · DOI
  9. De Forni, 2010, Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in HIV/AIDS., Br J Pharmacol, 161, 830, 10.1111/j.1476-5381.2010.00940.x · doi:10.1111/j.1476-5381.2010.00940.x
  10. Barbui, 2012, Front-line therapy in polycythemia vera and essential thrombocythemia., Blood Rev, 26, 205, 10.1016/j.blre.2012.06.002 · DOI
  11. Cervantes, 2014, How I treat myelofibrosis., Blood, 124, 2635, 10.1182/blood-2014-07-575373 · DOI · Paper page
  12. McGann, 2011, Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?, Curr Opin Hematol, 18, 158, 10.1097/MOH.0b013e32834521dd · DOI · Paper page
  13. Goldberg, 1990, Treatment of sickle cell anemia with hydroxyurea and erythropoietin., N Engl J Med, 323, 366, 10.1056/NEJM199008093230602 · DOI · Paper page
  14. Ware, 2010, How I use hydroxyurea to treat young patients with sickle cell anemia., Blood, 115, 5300, 10.1182/blood-2009-04-146852 · DOI · Paper page
  15. Charache, 1996, Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive “switching” agent., Medicine (Baltimore), 75, 300, 10.1097/00005792-199611000-00002 · DOI · Paper page
  16. Gladwin, 2002, Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease., Br J Haematol, 116, 436, 10.1046/j.1365-2141.2002.03274.x · DOI · Paper page
  17. Glover, 1999, Detection of nitrosyl hemoglobin in venous blood in the treatment of sickle cell anemia with hydroxyurea., Mol Pharmacol, 55, 1006, 10.1124/mol.55.6.1006 · DOI · Paper page
  18. Nahavandi, 2000, Nitric Oxide Metabolites in Sickle Cell Anemia Patients after Oral Administration of Hydroxyurea; Hemoglobinopathy., Hematology, 5, 335, 10.1080/10245332.2000.11746528 · DOI · Paper page
  19. Ignarro, 1987, Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical., Circ Res, 61, 866, 10.1161/01.RES.61.6.866 · DOI · Paper page
  20. Canalli, 2008, Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation., Haematologica, 93, 605, 10.3324/haematol.12119 · DOI · Paper page
  21. Almeida, 2012, Hydroxyurea and a cGMP-amplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice., Blood, 120, 2879, 10.1182/blood-2012-02-409524 · DOI · Paper page
  22. Turhan, 2002, Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm., Proc Natl Acad Sci USA, 99, 3047, 10.1073/pnas.052522799 · DOI · Paper page
  23. Fairbanks, 1992, Methods for measuring plasma hemoglobin in micromolar concentration compared., Clin Chem, 38, 132, 10.1093/clinchem/38.1.132 · DOI
  24. Kaul, 2004, Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice., Am J Physiol Heart Circ Physiol, 287, H293, 10.1152/ajpheart.01150.2003 · DOI · Paper page
  25. Senchenkov, 2011, P-selectin mediates the microvascular dysfunction associated with persistent cytomegalovirus infection in normocholesterolemic and hypercholesterolemic mice., Microcirculation, 18, 452, 10.1111/j.1549-8719.2011.00106.x · DOI
  26. Neumann, 1997, Induction of acute inflammatory lung injury by staphylococcal enterotoxin B., J Immunol, 158, 1862, 10.4049/jimmunol.158.4.1862 · doi:10.4049/jimmunol.158.4.1862
  27. Chang, 2008, Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion., Blood, 111, 915, 10.1182/blood-2007-04-084061 · DOI · Paper page
  28. Berra, 2014, Autologous transfusion of stored red blood cells increases pulmonary artery pressure., Am J Respir Crit Care Med, 190, 800, 10.1164/rccm.201405-0850OC · DOI
  29. Yoong, 2003, Binding of ovarian steroids to erythrocytes in patients with sickle cell disease; effects on cell sickling and osmotic fragility., J Steroid Biochem Mol Biol, 84, 71, 10.1016/S0960-0760(02)00266-2 · DOI
  30. Minneci, 2005, Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin., J Clin Invest, 115, 3409, 10.1172/JCI25040 · DOI · Paper page
  31. Qutub, 2010, Interactions of hemin with model erythrocyte membranes., J Phys Chem B, 114, 4529, 10.1021/jp100611n · DOI
  32. Steinberg, 2010, The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up., Am J Hematol, 85, 403, 10.1002/ajh.21699 · DOI · Paper page
  33. King, 2004, Nitric oxide production from hydroxyurea., Free Radic Biol Med, 37, 737, 10.1016/j.freeradbiomed.2004.02.073 · DOI
  34. Cokic, 2006, Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells., Blood, 108, 184, 10.1182/blood-2005-11-4454 · DOI
  35. Cokic, 2008, Hydroxyurea nitrosylates and activates soluble guanylyl cyclase in human erythroid cells., Blood, 111, 1117, 10.1182/blood-2007-05-088732 · DOI · Paper page
  36. Xu, 2011, Hydroxyurea enhances SMN2 gene expression through nitric oxide release., Neurogenetics, 12, 19, 10.1007/s10048-010-0268-z · DOI
  37. Kato, 2009, Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death., Br J Haematol, 145, 506, 10.1111/j.1365-2141.2009.07658.x · DOI
  38. Conran, 2003, Nitric oxide has a role in regulating VLA-4-integrin expression on the human neutrophil cell surface., Biochem Pharmacol, 66, 43, 10.1016/S0006-2952(03)00243-0 · doi:10.1016/s0006-2952(03)00243-0
  39. Conran, 2001, Nitric oxide regulates human eosinophil adhesion mechanisms in vitro by changing integrin expression and activity on the eosinophil cell surface., Br J Pharmacol, 134, 632, 10.1038/sj.bjp.0704295 · doi:10.1038/sj.bjp.0704295
  40. Qian, 2012, Exogenous, but not Endogenous Nitric Oxide Inhibits Adhesion Molecule Expression in Human Endothelial Cells., Front Physiol, 3, 3, 10.3389/fphys.2012.00003 · DOI
  41. El Nemer, 2012, HU for acute treatment of sickle VOC?, Blood, 120, 2777, 10.1182/blood-2012-08-447102 · DOI

Cited by

See all 82

Metadata

Authors
Almeida, C. B., Souza, L. E. B., Leonardo, F. C., Costa, F. T. M., Werneck, C. C., Covas, D. T., Costa, F. F., & Conran, N.
Venue
Blood
Published
2015-08-06
Volume
126
Issue
6
Pages
711-720
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2166262520
Cited by
82
References
11
FWCI
6.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. https://app.cochat.ai/papers/10.1182/blood-2014-12-616250
The paper
Almeida, C. B., Souza, L. E. B., Leonardo, F. C., Costa, F. T. M., Werneck, C. C., Covas, D. T., Costa, F. F., & Conran, N. (2015). Acute hemolytic vascular inflammatory processes are prevented by nitric oxide replacement or a single dose of hydroxyurea. Blood. https://doi.org/10.1182/blood-2014-12-616250

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.